期刊
DRUG DISCOVERY TODAY
卷 27, 期 4, 页码 1088-1098出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2021.10.020
关键词
Epigenetics; Drug discovery; Hit identi fi cation; Optimisation
This review provides an overview of the role of epigenetics in disease and the strategy of pharmacological intervention. It discusses the drug targets of epigenetics and the methods used for initial hit identification and chemical optimization. The review also highlights current challenges and future potential for epigenetics-based therapies.
Dysregulation of the epigenome is associated with the onset and progression of several diseases, including cancer, autoimmune, cardiovascular, and neurological disorders. Members from the three families of epigenetic proteins (readers, writers, and erasers) have been shown to be druggable using small-molecule inhibitors. Increasing knowledge of the role of epigenetics in disease and the reversibility of these modifications explain why pharmacological intervention is an attractive strategy for tackling epigenetic-based disease. In this review, we provide an overview of epigenetics drug targets, focus on approaches used for initial hit identification, and describe the subsequent role of structure-guided chemistry optimisation of initial hits to clinical candidates. We also highlight current challenges and future potential for epigenetics-based therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据